CASI Pharmaceuticals – executive interview – from EDISON
1,900
25
2023-5-12 15:30
CASI Pharmaceuticals & BioInvent
骶髂关节后路螺丝钉内固定
Total laparoscopic hysterectomy
Condylar Plate Fixation in the Distal Femur
TLH in a Woman with Extensive Adhesions
复位手法(拔伸牵引、回旋手法、反折手法、分骨手法、端提手法、扳正手法)
Hysteroscopy-guided laparoscopic resection of cesarean scar defect in 5 steps: The usefulness of non-perfusion hysteroscopy
李国新超声刀九字诀之综合应用:解剖肠系膜下动脉
0 bullet chats
Please Sign In first
Unauthorized reproduction is prohibited
CASI Pharmaceuticals is focused on building a portfolio of drugs which it intends to produce for Chinese and worldwide markets. Its products are focused on the hematology and oncology space, including its first product, Evomela, launched in China in 2019. The company is also developing an anti-CD19 CAR-T therapy, CNCT19, and the anti-CD38 drug CID-103, among others. The goal is to seek approval through new pathways that have opened in the quickly changing Chinese regulatory environment.
Comments 0
Please to post a comment~
Loading...
Related Suggestion